SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
16h
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
Under the FDA-authorized expanded access (IND 176297), urcosimod is being provided by OKYO Pharma for use in a patient with severe neuropathic corneal pain who has limited therapeutic options and no ...
OMAHA, NE - January 22, 2026 - PRESSADVANTAGE - Modern Vision Solutions has announced the publication of a new article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback